This study is a open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

This purpose of this study is to evaluate the safety and tolerability of study drug atezolizumab when administered with bevacizumab and FOLFOX in patients with gastric cancer. This study will also evaluate the safety and tolerability of atezolizumab administered with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

The purpose of this study is to find out more about talimogene laherparepvec (formerly known as OncoVEXGM-CSF), in people with advanced melanoma when given in combination with another drug called ipilimumab. Melanoma is a type of skin cancer. Advanced melanoma means the tumor is not removable by surgery or has spread to other parts of the body. The study will be conducted in two parts. Phase 1 of the study will see if talimogene laherparepvec in combination with ipilimumab is safe for people with advanced melanoma to take.

The purpose of this study is to test the safety, tolerability, and most effective dose of MGA271 in combination with ipilimumab (also called Yervoy®). MGA271 has not been approved by any Authority that regulates new medicines, including the US Food and Drug Administration (FDA). Ipilimumab is approved by the FDA for use in melanoma patients, but it is experimental for NSCLC and SCCHN patients. This is the first time that MGA271 and ipilimumab will be given in combination. At the beginning of the study, 3-9 patients will be treated with a low dose of MGA271 and ipilimumab.

The purpose of this research study is to find the highest safe dose of the drug MGCD265 that can be given to participants with advanced cancer. The safety of this drug, and the effect that it has on the participants disease and your body will also be studied. MGCD265 is a drug that works by blocking proteins that are important for cancer cells to grow. MGCD265 also prevents the growth of new blood vessels that help cancer tumors grow and spread. MGCD265 an investigational agent. This means that MGCD265 is not approved by the Food and Drug Administration (FDA).

The primary purpose of this research study is to determine how safe and tolerable MEDI0680 (AMP-514) and MEDI4736 are when given together in subjects with advanced cancers. MEDI0680 (AMP-514) and MEDI4736 are monoclonal antibodies that may prevent cancer growth and help the immune system eliminate the tumor. The idea behind developing these types of experimental drugs is that stimulating the immune system could be a different way of killing cancer cells, and by administering both antibodies, an important pathway can be targeted that may help your immune system eliminate tumors.

This is a phase 1/1b research study for adults with a diagnosis of an advanced solid tumor for which there are no standard therapies beyond those that may have already been received. This study involves an investigational (experimental) drug called MGCD516. Investigational means that MGCD516 is not approved by the U.S. Food and Drug Administration (FDA). MGCD516 is designed to block specific tyrosine kinases, which are proteins that are thought to cause tumors to grow. MGCD516 is also designed to slow down the growth of new blood vessels that help tumors to grow and spread.

The primary purpose of this research study is to test the effectiveness (how well the drug works), safety, and tolerability varlilumab and nivolumab (investigational drugs) together. Varlilumab and nivolumab are antibodies (types of human protein) that are manufactured in a laboratory and are being tested to see if they will allow the body’s immune system to work against tumor cells. This is the first time varlilumab and nivolumab have been tested together in humans.

The purpose of this protocol is to evaluate the effects of the combination of two drugs, LEE011 and MEK162, in melanoma (skin cancer), carrying specific alterations (also called mutated) in a gene called NRAS. The changes in NRAS gene may lead to cancer growth. This study will help to assess if patients with NRAS changes may be more responsive to treatment with LEE011 and MEK162. The study will identify the highest dose of LEE011 in combination with MEK162 that can be safely given to adults with certain cancers and furthermore, evaluate any changes in tumor size.

This study is being done to determine how patients with advanced or refractory solid tumors (cancer that continues to grow in spite of receiving standard treatment) respond to increasing doses of an investigational drug, CB-839, to determine the dose of CB-839 that can be given without causing severe side effects and to look for early signs of clinical activity. CB-839 blocks the production of glutamate which is critical for tumor cell growth. Investigational means that has not been approved by the United States Food and Drug Administration (FDA) for use outside of research studies.